Randomized Phase II Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Axitinib (Primary)
- Indications Adenocarcinoma
- Focus Therapeutic Use
- Acronyms AxitinibACC
- 10 Sep 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2017.
- 13 Jan 2017 Status changed from not yet recruiting to recruiting.
- 09 Aug 2016 New trial record